News & Events about Day One Biopharmaceuticals I.
FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team strengthened with executive appointments in clinical development and commercialization Pre-New Drug Application (NDA) meeting held April 19, 2023 with U....
Bank of America lowered shares of Day One Biopharmaceuticals (NASDAQ:DAWN Get Rating) from a buy rating to an underperform rating in a research note published on Tuesday , The Fly reports. DAWN has been the topic of a number of other reports. Piper Sandler raised their price target on shares...
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-progress poster from FIREFLY-2 and healthcare resource use for pediatric low-grade glioma care poster to be presented Company to host conference call and webcast on Sunday, June 4, 2023 at 6:00 PM ...
BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced an upcoming poster ...
HC Wainwright reissued their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN Get Rating) in a research report sent to investors on Tuesday , Benzinga reports. HC Wainwright currently has a $45.00 price objective on the stock. HC Wainwright also issued estimates for Day One ...